November 20，State Food and Drug Administration website display，Hengrui Pharmaceuticals, two major new medicines & mdash; & mdash; oxal sulfonic acid and long-term G-CSF review progress，The status of the Drug Review Center is all turned from & ldquo; queue up to review & rdquo; to & ldquo;。

    & ldquo; The development and listing of innovative drugs are the direction of future development，These two medicines are expected to be listed next year，This is also the innovative drug listing in Hengrui Pharmaceutical。& rdquo; November 20，Dai Hongbin, deputy general manager and director of My stake betting appHengrui Stake Sports BettingPharmaceutical, said in an exclusive interview with the "Investor News" reporter。

    Guangfa Securities Research Report estimates，Hengrui Pharmaceutical long-term G-CSF long-term sales can reach 2 billion yuan。Donghai Securities Analyst Qu Yan told reporters，Hengrui Pharmaceutical is a leading enterprise，The research and development of innovative drugs also walks ahead，but，From new medicine to the market to completion volume，It takes a certain time。

    This，Dai Hongbin also answered more cautious，Since the price is not determined，So，How much operating income can generate an innovative drug is uncertain。But he emphasized，Apatinibi sulfonic acid is much lower than the price of similar drugs Stake Sports Bettingabroad。Stake Sports BettingHe said，For a long time in the future，Hengrui Medicine hopes to achieve two legs of innovative drugs and generic drugs。